This PDF file includes:
Materials and Methods

Preparation of Aβ42 peptides
The recombinant Aβ(M1-42) peptide (MDAEFRHDSGY EVHHQKLVFF AEDVGSNKGA IIGLMVGGVV IA), here called Aβ42, was expressed in the E. coli BL21 Gold (DE3) strain (Stratagene, CA, U.S.A.) and purified as described previously with slight modifications (1). Briefly, the purification procedure involved sonication of E. coli cells, dissolution of inclusion bodies in 8 M urea, and ion exchange in batch mode on diethylaminoethyl cellulose resin followed by lyophylisation. The lyophilised fractions were further purified using Superdex 75 HR 26/60 column (GE Healthcare, Buckinghamshire, U.K.) and eluates were analysed using SDS-PAGE for the presence of the desired peptide product. The fractions containing the recombinant peptide were combined, frozen using liquid nitrogen, and lyophilised again. Compounds A-C, and I were purchased from ArkPharm (Illinois, USA); Compounds R and S were purchased from Molport (Riga, Latvia); and all other compounds were obtained from Sigma-Aldrich (Germany). All chemicals were of the highest purity available.
Preparation of Aβ42 samples for kinetic experiments
Solutions of monomeric Ab42 were prepared by dissolving the lyophilized Ab42 peptide in 6 M guanidinium hydrocholoride (GuHCl). Monomeric forms were purified from potential oligomeric species and salt using a Superdex 75 10 ⁄ 300 GL column (GE Healthcare) at a flowrate of 0.5 mL/min, and were eluted in 20 mM sodium phosphate buffer, pH 8 supplemented with 200 µM EDTA and 0.02% NaN3. The centre of the peak was collected and the peptide concentration was determined from the absorbance of the integrated peak area using e280 = 1490 l mol -1 cm -1 . The obtained monomer was diluted with buffer to the desired concentration and supplemented with 20 μM thioflavin T (ThT) from a 2 mM stock. All samples were prepared in low binding Eppendorf tubes on ice using careful pipetting to avoid introduction of air bubbles. Each sample was then pipetted into multiple wells of a 96-well half-area, low-binding, clear bottom and PEG coating plate (Corning 3881), 80
µL per well, in the absence and the presence of different molar-equivalents of small molecules.
ThT fluorescence assay
Assays were initiated by placing the 96-well plate at 37 ºC under quiescent conditions in a plate reader (Fluostar Omega, Fluostar Optima or Fluostar Galaxy, BMGLabtech, Offenburg, Germany). The ThT fluorescence was measured through the bottom of the plate using a 440 nm excitation filter and a 480 nm emission filter.
The ThT fluorescence was followed for three repeats of each sample. Data sets for bexarotene, compounds D-H, and compound J were taken from literature (2) for analysis and the creation of the KIA fingerprints.
Theoretical analysis
The time evolution of the total fibril mass concentration, M(t), is described by the following integrated rate law (3, 4) : Since surface-catalysed secondary nucleation is primarily responsible for the generation of Ab42 oligomers (3), a molecule that inhibits primary nucleation leaves relatively unaffected the overall number of oligomers produced during the aggregation process. Instead, since primary nucleation is the initial event leading to aggregation, the presence of this small molecule retards the formation of the critical amount of fibrils needed for surface-catalysed secondary nucleation to dominate, and thus effectively reduces the flux toward oligomers. By contrast, a molecule that inhibits secondary nucleation redirects free monomers towards elongation, and thus reduces the total overall number of oligomers on top of decreasing the flux toward oligomers (5).
We observed that the molecules affect the aggregation process of Ab42 to different extents (Figs. S1 and S6), and thus inhibit the primary nucleation and secondary nucleation pathways to different degrees (Figs. S2 and S8). Using the rate constants (kn, k2 or k+) in the presence of the molecules, we can estimate the reactive flux toward oligomers (r(t)) as (1, 6, 7) :
From the plots in Figs. 2A and 3A, we can predict the time of which the generation of oligomers reaches a peak, as well as the total number of oligomers generated over time (time integral of r(t)). In the presence of the molecules, as a result of the inhibition in both primary and secondary nucleation, the time taken for the oligomers to reach a peak is delayed, which consequently translates to a delay in the rate of oligomerization. The total number of oligomers generated over time is also reduced in the presence of the small molecules. The evolution of the increase in peak time for the flux toward oligomers, the reduction in the total number of oligomers formed, and Generation of a 3D model of the pharmacophore 3D conformations of the positive compounds were first generated using CORINA (9).
These conformations (in a mol2 format) were used as input with default options, and the algorithm for PharmaGist was subsequently employed to generate the pharmacophore model (10) . The features of the pharmacophore calculated was matched by all the molecules that were used as the inputs. The pharmacophore was subsequently visualised using ROCS (11, 12).
Calculation of physico-chemical properties of the small molecules
Constitutional descriptors and molecule properties were calculated using E-Dragon Table S1 : Summary of the three parameters in the KIA fingerprints: (1) OIC50 PT , which is associated with a delay in the flux toward oligomer, (2) OIC25 T , which is associated with a reduction in the total number of oligomers generated, and (3) the macroscopic parameter KIC50 M , which describes the overall rate of aggregate formation. Table S4 : Effects on the inhibition of Ab42 aggregation associated with the physicochemical properties of the polar group R1 (Fig. 3) in rhodanine-based compounds.
Upon the substitution of a more polar group, molecule S does not inhibit significantly the aggregation of Ab42. Table S5 : Effects on Ab42 oligomer production associated with the physico-chemical properties of the apolar group R3 (Fig. 3) in rhodanine-based compounds. Values in green indicate an increase in potency with respect to Molecule K.
